Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Adherence With Fixed Versus Unfixed Glaucoma Therapy

This study has been completed.
Information provided by (Responsible Party):
AGP Konstas, Aristotle University Of Thessaloniki Identifier:
First received: January 20, 2011
Last updated: May 9, 2014
Last verified: May 2014
A 6-month, parallel, non-interventional trial investigating the level of adherence and the impact of dosing in open-angle glaucoma patients who receive either unfixed therapy with latanoprost once in the evening and timolol twice daily, or latanoprost/timolol fixed combination therapy once in the evening. All patients participating in this observational study will be monitored for their adherence with the use of Medication Event Monitoring System (MEMS). At the end of treatment periods treatment satisfaction will be assessed with selected questions from the Treatment Satisfaction Survey-Intraocular Pressure survey. This study will monitor objectively, for the first time, adherence and intraocular pressure control with fixed versus unfixed therapy. Finally it will help us to elucidate the impact of dosing (once-a-day versus three-times-daily) on the level of adherence in glaucoma.

Primary Open-angle Glaucoma
Ocular Hypertension
Exfoliation Glaucoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A 3-month, Observational Study Investigating With Electronic Monitoring the Level of Adherence and Treatment Satisfaction With Latanoprost/Timolol Fixed Combination Versus Unfixed Therapy in Open-angle Glaucoma

Resource links provided by NLM:

Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:
  • Rate of adherence [ Time Frame: 6 months ]
    Rate of asherence with fixed vs unfixed glaucoma therapy

Secondary Outcome Measures:
  • Ocular surface evaluation [ Time Frame: 6 months ]
    Objective and subjective signs of ocular surface health

  • Treatment satisfaction [ Time Frame: 6 months ]
    To document satisfaction with therapy this study will employ questions selected from a validated treatment satisfaction questionnaire (questions 10-15, Treatment Satisfaction Survey-Intraocular Pressure) as published by Day et al (Eye 2006; 20: 583-590). The survey will assess the level of satisfaction and overall quality-of-life with latanoprost/timolol fixed combination versus unfixed therapy in this study.

Enrollment: 132
Study Start Date: May 2009
Study Completion Date: July 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Treatment with fixed combination
Patients who receive treatment with latanoprost/timolol fixed combination
Treatment with unfixed therapy
Patients who receive latanoprost and timolol therapy


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All patients who use latanoprost/timolol fixed combination therapy with once-a-day dosing in the evening

All patients already treated with timolol twice daily and latanoprost once in the evening


Inclusion Criteria:

  • Patient is between 21-80 years old
  • Patient has ocular hypertension or open-angle glaucoma Patient receives therapy and is well controlled on fixed or unfixed latanoprost and timolol therapy
  • Untreated IOP >19 mm Hg <33 mm Hg at baseline (10:00 hour)
  • Open normal appearing angles
  • Patient had at least a 20% reduction vs untreated baseline on current therapy
  • Patient has early or moderate glaucoma (< 14 decibel; 0.8 or better cupping)
  • Distance best corrected Snellen visual acuity greater than 1/10

Exclusion Criteria:

  • Contraindication to timolol or prostaglandin therapy
  • History of lack of response to any medication (< 10%)
  • Patient does not understand the instructions and will not comply to medications
  • Patient can not attend follow up
  • Patient is a female of childbearing potential, or lactating mother
  • History of trauma, inflammation, surgery, past use of steroids (within 2 months), severe dry eyes and use of contact lenses
  • Sign of ocular infection
  • A corneal abnormality that may affect IOP measurements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01281020

Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital
Thessaloniki, Greece, 546 36
Sponsors and Collaborators
Aristotle University Of Thessaloniki
Principal Investigator: Anastasios G Konstas, MD, PhD Glaucoma Unit, 1st University Department of Ophthalmology
  More Information

Responsible Party: AGP Konstas, Professor in Ophthalmology, Aristotle University Of Thessaloniki Identifier: NCT01281020     History of Changes
Other Study ID Numbers: NIS50/01/08
Study First Received: January 20, 2011
Last Updated: May 9, 2014

Keywords provided by Aristotle University Of Thessaloniki:
Fixed combination therapy

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Exfoliation Syndrome
Eye Diseases
Iris Diseases
Uveal Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents processed this record on April 21, 2017